LENSAR (LNSR) Fundamentals 2026 — P/E 5.9x, Revenue Analysis | SniperIQ
LENSAR (LNSR) is a US-listed Healthcare company in Medical - Equipment & Services with a market capitalization of $69M, trading at $5.74 on the NASDAQ. This SniperIQ fundamentals page covers LENSAR's valuation (P/E 5.9x, P/B 2.8x), profitability (net margin 50.9%), revenue ($58M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is LENSAR's market cap?
LENSAR (LNSR) has a market capitalization of approximately $69M, trading at $5.74 on the NASDAQ. Market cap moves with the live share price.
What is LENSAR's P/E ratio?
LENSAR's trailing twelve-month P/E ratio is 5.9x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is LENSAR?
LENSAR runs a net profit margin of 50.9%, a gross margin of 45.3%, and an operating margin of -28.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does LENSAR generate?
LENSAR reported revenue of $58M for fiscal year 2025, with net income of -